1. Home
  2. MRKR vs TRT Comparison

MRKR vs TRT Comparison

Compare MRKR & TRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • TRT
  • Stock Information
  • Founded
  • MRKR N/A
  • TRT 1958
  • Country
  • MRKR United States
  • TRT United States
  • Employees
  • MRKR N/A
  • TRT N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • TRT Industrial Machinery/Components
  • Sector
  • MRKR Health Care
  • TRT Technology
  • Exchange
  • MRKR Nasdaq
  • TRT Nasdaq
  • Market Cap
  • MRKR 30.7M
  • TRT 27.6M
  • IPO Year
  • MRKR N/A
  • TRT N/A
  • Fundamental
  • Price
  • MRKR $3.47
  • TRT $6.30
  • Analyst Decision
  • MRKR Strong Buy
  • TRT
  • Analyst Count
  • MRKR 1
  • TRT 0
  • Target Price
  • MRKR $19.00
  • TRT N/A
  • AVG Volume (30 Days)
  • MRKR 91.1K
  • TRT 7.4K
  • Earning Date
  • MRKR 11-14-2024
  • TRT 02-10-2025
  • Dividend Yield
  • MRKR N/A
  • TRT N/A
  • EPS Growth
  • MRKR N/A
  • TRT N/A
  • EPS
  • MRKR N/A
  • TRT 0.24
  • Revenue
  • MRKR $5,395,849.00
  • TRT $42,312,000.00
  • Revenue This Year
  • MRKR $35.94
  • TRT N/A
  • Revenue Next Year
  • MRKR N/A
  • TRT N/A
  • P/E Ratio
  • MRKR N/A
  • TRT $26.88
  • Revenue Growth
  • MRKR 79.04
  • TRT N/A
  • 52 Week Low
  • MRKR $2.44
  • TRT $4.64
  • 52 Week High
  • MRKR $6.16
  • TRT $7.88
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 50.16
  • TRT 46.82
  • Support Level
  • MRKR $3.47
  • TRT $5.91
  • Resistance Level
  • MRKR $5.95
  • TRT $6.88
  • Average True Range (ATR)
  • MRKR 0.63
  • TRT 0.23
  • MACD
  • MRKR 0.01
  • TRT -0.05
  • Stochastic Oscillator
  • MRKR 16.99
  • TRT 48.04

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About TRT Trio-Tech International

Trio-Tech International is a provider of third-party semiconductor testing and burn-in services through its laboratories in Southeast Asia. The company operates in four segments namely Manufacturing, Testing services, Distribution, and Real Estate. Its Manufacturing segment manufactures both front-end and back-end semiconductor test equipment and related peripherals. The Testing Services segment renders services to the manufacturer and purchaser of semiconductors and other entities. Its Distribution segment is involved in the distribution of its products. The company's Real Estate segment consists of investment in real estate. Its geographical area of operations includes the United States, Singapore, Malaysia, Thailand, and China. It derives maximum revenue from Testing services Segment.

Share on Social Networks: